Atlanta, GA – May 2025 –
MAGISNAT OMICS LLC, a biotechnology spin-off specializing in omics sciences, commemorated its first year of operation on May 13 and 14 with two public events at the Georgia State Capitol and Atlanta Tech Park. The events gathered policymakers, researchers, academics, and entrepreneurs to assess the company’s impact and explore future directions in biotech, emphasizing omics technologies and intellectual property development.
Held at the Georgia State Capitol, the first event explored how scientific research can intersect with policy and institutional goals. MAGISNAT introduced its work in multi-omics—a field combining genomic, metabolomic, proteomic, microbiomic, and environmental data to construct detailed health profiles. The approach targets chronic non-communicable diseases, aiming to enhance preventive strategies and improve healthcare outcomes.
The audience included representatives from academia, industry, and government. Dr. Vishnu Suppiramaniam, Associate Dean at Kennesaw State University, discussed the role of universities in translating research into practice. He emphasized how structured collaborations with biotech companies provide students with applied learning opportunities, while institutions and companies benefit from mutual access to research expertise and infrastructure.
Dr. Suppiramaniam also highlighted overlapping interests between MAGISNAT’s research and Kennesaw State’s focus areas. These alignments may serve as a foundation for future collaboration in research, training, and innovation, advancing translational science and strengthening regional biotech capabilities.
Key MAGISNAT figures also contributed. Dr. Stephen Thadeus Connelly, co-founder and UCSF Professor, spoke on the role of translational research in connecting discovery to application. Dr. Matteo Bertelli, MAGISNAT President, detailed recent patents. CEO Dr. Kevin Donato shared a strategy for translating science into clinical platforms, and Dr. Giuseppe Oriani of Savills Investment Management SGR, outlined biotech’s potential to attract investment and support entrepreneurial growth.
Institutional guests included Neal VanMarter (Senator Jon Ossoff’s office), Filiberto Calascibetta (Honorary Consul of Italy), Nick Masino (Gwinnett Chamber of Commerce), and Robin Bienfait (Atlanta Tech Park). Dr. Pietro Chiurazzi, Associate Professor at the Catholic University of Rome and MAGISNAT co-founder, moderated the session.
The second event, held at Atlanta Tech Park, focused on presenting the company’s current research and patented technologies. The venue, known for fostering high-tech innovation, hosted stakeholders from science, entrepreneurship, and public service sectors.
Five key projects were introduced: a diagnostic platform using mass spectrometry and breath analysis to detect inflammation from environmental exposure; a neuromodulation technique delivering neuroactive molecules intranasally to regulate appetite; a model to analyze protein glycosylation stress linked to diet; a proprietary suite of bioinformatics tools for multi-omic data analysis; and a treatment targeting AKR1C2 to limit fat accumulation in lipedema.
MAGISNAT researchers Drs. Kristjana Dhuli, Cecilia Micheletti, Alessandro Macchia, and Jurgen Kaftalli presented the scientific basis and clinical implications of each patent, underscoring the company’s focus on solutions that are both scientifically sound and applicable to real-world health challenges.
Opening remarks were delivered by Robin Bienfait, Nashlee Young (Atlanta Tech Park), Bertrand Lapoire (City of Peachtree Corners), and Nick Masino, reinforcing local support for biotechnology initiatives.
Together, the two events reflected a shared belief: that innovation in omics, when supported by academic cooperation and a responsive institutional framework, can produce tangible health benefits. MAGISNAT, through its patents and partnerships, is positioned to contribute meaningfully to the future of precision medicine.
